Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.

Recent studies suggest benefits of these systems for people with type 2 diabetes, as well.

最近的研究表明，这些系统对于2型糖尿病患者也有益处。

To evaluate the effects of AID systems on glycemic outcomes in people with type 2 diabetes requiring insulin.

评估自动胰岛素输送系统对需要胰岛素的2型糖尿病患者的血糖控制结果的影响。

data_sources

The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched through 10 March 2025.

通过2025年3月10日，对PubMed、Embase、Cochrane图书馆和ClinicalTrials.gov数据库进行了检索。

This study was registered with PROSPERO (CRD420251036184).

本研究已在PROSPERO注册（CRD420251036184）。

study_selection

Nine studies (n = 1,530 participants) were included that evaluated AID systems in people with type 2 diabetes reporting continuous glucose monitoring outcomes.

纳入了九项研究（n = 1,530名参与者），这些研究评估了在2型糖尿病患者中使用自动胰岛素输送系统，并报告了连续血糖监测结果。

data_extraction

Data were collected on study characteristics and outcomes including time in range (TIR) (3.9-10.0 mmol/L [70-180 mg/dL]), time above range (TAR) (>10.0 mmol/L [>180 mg/dL]), time below range (TBR) (<3.9 mmol/L [<70 mg/dL]), mean glucose, and HbA1c.

收集了研究特征和结果的数据，包括时间在范围内（TIR）（3.9-10.0 mmol/L [70-180 mg/dL]），时间超出范围（TAR）（>10.0 mmol/L [>180 mg/dL]），时间低于范围（TBR）（<3.9 mmol/L [<70 mg/dL]），平均血糖和糖化血红蛋白（HbA1c）。

We performed a single-arm meta-analysisusing a random-effects model.

我们使用随机效应模型进行了一项单臂荟萃分析。

data_synthesis

AID systems significantly increased TIR by 16.06% (95% CI 10.48-21.65), changed TAR by -15.90% (95% CI -21.44 to -10.36), changed HbA1c by -1.27% (95% CI -2.06 to -0.48), and changed mean glucose by -21.34 mg/dL (95% CI -32.06 to -10.62) or 1.19 mmol/L (95% CI -1.78 to -0.59).

AID系统显著提高了时间在目标范围内（TIR）16.06%（95% 置信区间10.48-21.65），改变了时间高于目标范围（TAR）-15.90%（95% 置信区间-21.44至-10.36），改变了糖化血红蛋白（HbA1c）-1.27%（95% 置信区间-2.06至-0.48），并改变了平均血糖水平-21.34 mg/dL（95% 置信区间-32.06至-10.62）或1.19 mmol/L（95% 置信区间-1.78至-0.59）。

There was a modest yet significant reduction in TBR.

存在适度但显著的血糖低于目标范围（TBR）的降低。

There were no changes in body weight or BMI.

体重或体质指数（BMI）没有变化。

limitations

Heterogeneous study designs, including only three randomized controlled trials, and imputed missing data.

研究设计异质性大，仅包括三项随机对照试验，并且使用了估算的缺失数据。

Conclusions

AID systems improved glucose control in a diverse population of individuals with type 2 diabetes requiring insulin therapy with reduction in hypoglycemia.

AID系统在需要胰岛素治疗的2型糖尿病患者中改善了血糖控制，并减少了低血糖的发生。

These findings support recommendations for AID systems use in future type 2 diabetes management guidelines.

这些发现支持在未来的2型糖尿病管理指南中推荐使用AID系统的建议。